Skip to main content
Premium Trial:

Request an Annual Quote

Newomics Closes $3.9M Series A Round

NEW YORK (GenomeWeb) – Mass spec technology firm Newomics has closed a $3.9 million Series A funding round.

The Berkeley, California-based company closed the round on Wednesday, said Daojing Wang, Newomics' founder and CEO, adding that it surpassed its initial target of $3.5 million. The round was led by the Berkeley Catalyst Fund and the Photon Fund.

According to Wang, the funds will be used to expand the company's management team and complete commercialization of its silicon-based multinozzle emitter array (MEA) technology, which the company said increases the sensitivity and robustness of LC-MS, as well as develop assays based on that technology.

The MEA device consists of a series of multinozzle emitters arranged in a circular array on a silicon chip. The multiple emitters allow for higher-throughput experiments, as each emitter can be interfaced to a separate LC system, which enables rapid sequential or parallel mass spec analyses. The increase in nozzles provides an improvement in sensitivity proportional to the square root of the number of nozzles per emitter.

Wang and his co-founder Pan Mao launched Newomics in 2013 as a spinout from the Lawrence Berkeley National Laboratory, where the two invented the MEA technology.

The Scan

PLOS Papers on SARS-CoV-2 Diversity in Delaware, Metastatic Breast Cancer, Adiposity GWAS

In PLOS this week: genomic analysis of SARS-CoV-2 isolates from Delaware, gene expression and protein-protein interaction patterns in metastatic breast cancer, and more.

Omicron's Sewage Path

The New York Times writes that testing sewage is helping public health officials track Omicron.

IBM Sells Part of Watson Health

The Wall Street Journal reports IBM is selling part of its Watson Health business to an investment firm.

Identifying the Right Whales

The Boston Globe writes that genetic testing has helped identify North American right whales and find that weaning can take place earlier than thought.